These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2632268)

  • 1. A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U).
    Weiss GR; Sarosy GA; Shenkenberg TD; Williams T; Clendeninn NJ; Von Hoff DD; Woolley JL; Liao SH; Blum MR
    Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1867-73. PubMed ID: 2632268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule.
    Adamson PC; Balis FM; Miser J; Wells RJ; Bleyer WA; Williams TE; Gillespie A; Penta JS; Clendeninn NJ; Poplack DG
    Cancer Res; 1990 Aug; 50(15):4464-7. PubMed ID: 2369724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation.
    Roberts JD; Poplin EA; Tombes MB; Kyle B; Spicer DV; Grant S; Synold T; Moran R
    Cancer Chemother Pharmacol; 2000; 45(2):103-10. PubMed ID: 10663624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule.
    Adamson PC; Balis FM; Miser J; Arndt C; Wells RJ; Gillespie A; Aronson L; Penta JS; Clendeninn NJ; Poplack DG
    Cancer Res; 1992 Feb; 52(3):521-4. PubMed ID: 1732038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
    Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
    Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I clinical and pharmacokinetic study of the oral and the oral/intravenous administration of menogaril.
    Weiss GR; Brown TD; Kuhn JG; Von Hoff DD; Earhart RH; Adams WJ; Brewer JE; Hosley JD; Kasunic DA
    Invest New Drugs; 1993 Feb; 11(1):17-27. PubMed ID: 8349432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
    Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
    J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration.
    Feun LG; Gonzalez R; Savaraj N; Hanlon J; Collier M; Robinson WA; Clendeninn NJ
    J Clin Oncol; 1991 Mar; 9(3):464-7. PubMed ID: 1999717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of piritrexim and DTIC using an alternating dose schedule in metastatic melanoma.
    Feun LG; Robinson WA; Savaraj N; Gonzalez R; Liebmann A; Offenhauser K; Clendeninn NJ
    Am J Clin Oncol; 1995 Dec; 18(6):488-90. PubMed ID: 8526190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicentre 12-week open study of a lipid-soluble folate antagonist, piritrexim in severe psoriasis.
    Perkins W; Williams RE; Vestey JP; Tidman MJ; Layton AM; Cunliffe WJ; Saihan EM; Klaber MR; Manna VK; Baker H
    Br J Dermatol; 1993 Nov; 129(5):584-9. PubMed ID: 8251356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of LY309887: a specific inhibitor of purine biosynthesis.
    Budman DR; Johnson R; Barile B; Bowsher RR; Vinciguerra V; Allen SL; Kolitz J; Ernest CS; Kreis W; Zervos P; Walling J
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):525-31. PubMed ID: 11459206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
    Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
    Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
    Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
    Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
    Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
    Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.